I
ncreased adiposity is a major risk factor for cardiovascular disease and NIDDM (1) . Genetic determinants of the degree of adiposity and body fat distribution have been demonstrated by twin and adoption studies, and the heritability (h 2 ) of obesity has been estimated to be as high as 0.90 (2). However, the major genes underlying the heritable contribution to body fatness in humans have remained elusive.
Rodent models of genetically determined obesity provide excellent candidate genes for evaluation in humans. The linkage of obesity-related phenotypes in humans to genomic regions homologous to rodent leptin (Lep) (3) and leptin receptor (Lepr) (4, 5) has been recently demonstrated. The recent cloning of Lepr, which is mutant in the diabetes (Lepr^) mouse and in fatty (Lepr fa ) and Koletsky (Lepr fqf ) rats (6-9), the mapping of this gene (LEPR) to Ip32 in humans (10) , and the description of the genomic structure of LEPR and two polymorphic intronic microsatellites (11) have provided the necessary reagents for the evaluation of LEPR in the genetics of human obesity.
Because the phenotype associated with genetic defects in Lepr in Lepr db /Lepr db mice and Lepr fa /Lepr fa rats is profound early-onset obesity, we sought to identify allelic variations in LEPR, which may be responsible for the genetic variation in adiposity in humans. To maximize the likelihood of the detection of such sequence variants, we examined genomic DNA from a total of 229 obese and lean adults and children, ascertained in medical centers around the U.S. (New York, New York; New Orleans, Louisiana; and Huntington, West Virginia). The study sample was predominantly Caucasian, but also included blacks and Hispanics, ascertained through several pediatric and adult endocrinology and obesity centers throughout the U.S. Adiposity was assessed by BMI (determined as weight [in kilograms] divided by height [in meters] squared). Twenty milllliters of blood was drawn for leukocyte isolation and plasma leptin determination (12) .
The initial study population comprised 167 obese adults and children (mean BMI, 42.0 kg/m 2 ) and 27 lean adults and children (mean BMI, 23.2 kg/m 2 ). We used single-strand conformation analysis (SSCA) to screen all subjects for variation in coding exons 5 and 18, the exons containing, respectively, the sequence that is mutant in the fa rat (Lepr fa ) (13) and the sequence that is incorrectly spliced in the db mouse (Lepr db ) ( Fig. 1 
) (7).
Genomic DNA was extracted from whole blood, using standard methodology (13) . Polymerase chain reactions (PCRs) and sequencing were performed as previously described (11) . Primers for all 18 coding exons were as previously described (11) or divided into smaller fragments (primer sequences available by request). Of the PCR reaction, 5 ul was heat denatured, immediately placed on ice, and electrophoresed on a 6% polyacrylamide gel with or without 10% glycerol at 5 W at room temperature for 24 h.
We also screened all 18 coding exons of the "long" form of LEPR ("Rb") containing the membrane spanning domain (6, 14) in 32 morbidly obese individuals (BMI, >50 kg/m 2 ), including five children, by SSCA. In addition, we screened 14 morbidly obese adults (mean BMI, 66.5 kg/m 2 ) by measuring fasting plasma leptin concentrations with a solid-phase sandwich enzyme immunoassay (12) . These plasma leptin concentrations were compared with regression plots (by sex and menopausal status) of plasma leptin versus BMI for a group of 67 lean and obese individuals (12) . Two female subjects were identified with plasma leptin concentrations that were 36 and 98% above those predicted for BMI. In these two individuals, all 18 coding exons of the long form of LEPR were directly sequenced and compared with a normal weight control subject. No unique exonic sequence variants were detected in the two obese subjects with relative elevations in plasma leptin concentrations.
As indicated in Fig. 1 , using PCR primer pairs located in sequences flanking the 18 coding exons of LEPR (11), we identified by SSCA and direct sequencing three allelic variants associated with amino acid changes (LyslO9Arg, Gln223Arg, and Lys656Asn), three silent mutations (nt 1222 T^C, nt 3217 A-*G, and nt 3250 G-»A), and four intronic sequence variants (Fig. 1) . Thus, a total of six differences from the originally published LEPR cDNA sequence (6) were detected, three of which have been previously reported (nt 519/LyslO9Arg, nt 861/Gln223Arg, and nt 3250) (15) . Of the three nucleotide alterations that produce amino acid changes, Gln223Arg and Lys656Asn result in changes in charge (neutral to positive and positive to neutral, respectively) and are, therefore, the mostly likely to have functional consequences. In addition, all three amino acids (Lys 109, Gln223, and Lys656) are conserved among rat, mouse, and human species (6, 16) . It will be necessary to test each amino acid variant alone and in combination, using in vitro binding and signal transduction assay systems to determine their effects on leptin binding and signal transduction (8) .
Although many polymorphisms were observed in obese patients, notably absent were any mutations that would result in an obvious loss of function such as nonsense, frameshift, or deletion/insertion mutations. Although mutations in specific splice variants as observed in the Lepr^ mouse (7, 14) are more directly analyzed with mRNA, no alterations in splice sites were noted. Also, Considine et al. (15) found no gross alterations in the size or quantity of LEPR message, or cDNA sequence, in hypothalamic mRNA obtained from eight obese human subjects. However, not all intronic sequences were analyzed in our subjects; therefore, undetected mutations producing novel splice sites may exist.
The allele frequencies for the three coding sequence variants were determined in the original 167 obese and 27 lean subjects originally used to examine exons 5 and 18. The allele frequencies, by racial group and obesity phenotype, are shown in Table 1 . There is little difference in allele frequency by racial group. Formal association and sib-pair studies of earlyonset, extreme, and milder degrees of obesity with multiple phenotypic measures related to in vitro studies of receptor binding and signal transduction will be necessary to evaluate the possible clinical significance of these three amino acid variants in LEPR completely. Such studies are underway (17) .
The present genetic analysis was limited to the coding sequence of a single splice ("long" form) variant of LEPR. However, other splice variants and relevant regulatory sequences remain unexplored. Multiple markers, including two intronic microsatellites, are now available spanning the length of LEPR (11) and provide the necessary reagents for association studies and haplotype analysis to determine whether, in a particular population, there are likely to be sequence variants (in linkage disequilibrium with particular alleles of the polymorphic markers) that could account for a significant component of relevant phenotypic variance. ) subjects originally used for mutation detection in exons 5 and 18 were subsequently genotyped for the three amino acid variants of LEPR shown in Fig. 1 . Genotypes were determined for the exon 2 variant by restriction digestion analysis using Hae III with a modified reverse primer, which introduces a Hae III site in the ARG 109 allele; for the exon 4 variant by restriction digestion analysis using Msp I, which restricts the ARG 223 allele; and for exon 12 by SSCA. Allele frequencies by race or obesity phenotype are presented.
